Dr. Patnaik on Activity of SL-401 in Chronic Myelomonocytic Leukemia

Mrinal Patnaik, MBBS
Published: Friday, Dec 30, 2016



Mrinal Patnaik, MBBS, hematologist, Mayo Clinic, discusses the encouraging results seen in a phase II trial evaluating the activity of SL-401 in patients with advanced, high-risk myeloproliferative neoplasms (MPN), including chronic myelomonocytic leukemia (CMML).

SL-401 is a novel targeted therapy directed to the interleukin-3 receptor (CD123), a target overexpressed by many hematologic malignancies. CD123 has been shown to be expressed on MPN cells as well as microenvironmental immune cells, specifically plasmacytoid dendritic cells (pDCs), in the bone marrows of some patients with MPN including CMML.

Initial dosing of SL-401 appears to be well tolerated thus far in patients with MPN and CMML, with no unexpected toxicities observed.

The hope, says Patnaik, is that these researchers can improve patients' blood counts, reduce transfusion dependency, improve symptoms, and also produce improvement in terms of both overall and complete responses.
SELECTED
LANGUAGE


Mrinal Patnaik, MBBS, hematologist, Mayo Clinic, discusses the encouraging results seen in a phase II trial evaluating the activity of SL-401 in patients with advanced, high-risk myeloproliferative neoplasms (MPN), including chronic myelomonocytic leukemia (CMML).

SL-401 is a novel targeted therapy directed to the interleukin-3 receptor (CD123), a target overexpressed by many hematologic malignancies. CD123 has been shown to be expressed on MPN cells as well as microenvironmental immune cells, specifically plasmacytoid dendritic cells (pDCs), in the bone marrows of some patients with MPN including CMML.

Initial dosing of SL-401 appears to be well tolerated thus far in patients with MPN and CMML, with no unexpected toxicities observed.

The hope, says Patnaik, is that these researchers can improve patients' blood counts, reduce transfusion dependency, improve symptoms, and also produce improvement in terms of both overall and complete responses.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x